Introduction
The landscape of non-small-cell lung cancer (NSCLC) treatment has rapidly evolved with the advent of molecular-targeted therapies. Among the diverse genetic alterations identified in NSCLC, HER2 (ERBB2) mutations represent an important but historically challenging subset. Occurring in approximately 2 to 4% of NSCLC cases, HER2 mutations have been associated with a distinct biological profile and potential responsiveness to targeted agents. Despite the recognition of HER2 as a therapeutic target in breast and gastric cancers, effective targeted treatments for HER2-mutant NSCLC remain limited. The recent development and clinical evaluation of sevabertinib, a novel oral reversible tyrosine kinase inhibitor (TKI), aims to address this unmet need.
